Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

Talal Hilal; Vinay Prasad

doi:10.1038/s41571-018-0087-y

Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

Talal Hilal, Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Comment/debate › peer-review

7 Scopus citations

Abstract

The approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and confirm the hypothesis.

Original language	English (US)
Pages (from-to)	727-728
Number of pages	2
Journal	Nature Reviews Clinical Oncology
Volume	15
Issue number	12
DOIs	https://doi.org/10.1038/s41571-018-0087-y
State	Published - Dec 1 2018

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/s41571-018-0087-y

Cite this

@article{2737bf7361e64f49bfbdf6a8e5dc5cd3,

title = "Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission",

abstract = "The approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and confirm the hypothesis.",

author = "Talal Hilal and Vinay Prasad",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41571-018-0087-y",

language = "English (US)",

volume = "15",

pages = "727--728",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

AU - Hilal, Talal

AU - Prasad, Vinay

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and confirm the hypothesis.

AB - The approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and confirm the hypothesis.

UR - http://www.scopus.com/inward/record.url?scp=85053435097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053435097&partnerID=8YFLogxK

U2 - 10.1038/s41571-018-0087-y

DO - 10.1038/s41571-018-0087-y

M3 - Comment/debate

C2 - 30181661

AN - SCOPUS:85053435097

SN - 1759-4774

VL - 15

SP - 727

EP - 728

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 12

ER -

Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this